Quest Diagnostics Incorporated (DGX) is currently priced at $196.98, reflecting a 0.178% increase from the previous close of $196.63. Trading volume is at $101,539, representing a 10.09% rise compared to the average.
DGX's latest quarterly earnings report, announced on Monday, April 20th, surpassed expectations with a consensus estimate EPS of 2.34.
The forward dividend yield is 1.75%, with a dividend per share of 86 cents MRQ and $3.26 TTM, indicating a stable financial position.
Jefferies reaffirmed a "Buy" rating for DGX on April 21st, with a price of $206.79. Investors are advised to hold their positions.
Operating cash flow stands at $278 million, with a net decrease in cash of $27 million. Notably, no common stock was repurchased during this period.
DGX reported a revenue of $2.90 billion, leading to a net income of $252 million. The earnings per share (EPS) and diluted EPS were $2.27 and $2.24, respectively.
Key ratios include a net profit margin of 8.7%, return on assets of 1.51%, and a price-to-earnings ratio of 21.39, all indicating a positive financial performance.
With total assets amounting to $16.67 billion and total liabilities at $9 billion, DGX shows a healthy financial standing with a net debt of $6.59 billion.
This comprehensive analysis showcases DGX's strong performance and financial stability in the current market environment.
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.